FREEDOM评分外部验证:指导糖尿病多支病变患者CABG与PCI个体化决策
本研究在SYNTAX和BEST试验中筛选702例糖尿病多支病变患者,外部验证FREEDOM评分预测5年MACE及CABG vs PCI治疗获益的能力。结果显示CABG较PCI降低5年MACE(12.4% vs 20.3%,log-rank P=0.021),PCI组区分度和校准良好(C-index 0.69),CABG组中等(C-index 0.61),评分可识别一定治疗获益异质性。
要点
- FREEDOM评分可识别糖尿病多支病变患者CABG vs PCI的5年MACE治疗获益异质性。
- 外部验证中PCI组区分度良好(C-index 0.69),CABG组中等(C-index 0.61)。
- CABG较PCI降低5年MACE(12.4% vs 20.3%,log-rank P=0.021)。
核心结论
- FREEDOM评分可识别CABG vs PCI治疗5年MACE获益的异质性,但需进一步前瞻性验证后方可用于临床决策。
研究设计与样本
- 在SYNTAX和BEST试验中筛选702例糖尿病多支病变患者,以模拟FREEDOM受试者进行外部验证。
- 分别评估PCI组和CABG组的区分度(C-index)与校准度(校准图),并评估评分预测CABG vs PCI治疗获益的能力。
主要发现
- CABG较PCI降低5年MACE发生率(12.4% vs 20.3%;log-rank P=0.021),且不受吸烟史影响(Pinteraction=0.975)。
- PCI组区分度和校准度良好(C-index 0.69;斜率0.96,截距-0.24)。
- CABG组区分度和校准度中等(C-index 0.61;斜率0.61,截距-0.53)。
- FREEDOM评分显示CABG vs PCI治疗获益存在一定异质性。
临床怎么用
- 在糖尿病多支病变患者中可参考FREEDOM评分评估CABG vs PCI的个体化治疗获益,但需注意CABG组校准中等。
- 临床应用前应等待进一步前瞻性验证结果。
局限性
- 研究为基于SYNTAX和BEST试验数据的外部验证,非前瞻性设计。
- CABG组区分度和校准度仅为中等(C-index 0.61;斜率0.61,截距-0.53)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although randomized trials have established that coronary artery bypass grafting (CABG) is, on average, the most effective revascularization strategy compared with percutaneous coronary intervention (PCI) in patients with diabetes and multivessel disease (MVD), individual patients differ in many characteristics that can affect the benefits and harms of treatment. The FREEDOM (Future Revascularization Evaluation in Patients with Diabetes Mellitus) score was developed to predict different outcomes with CABG vs PCI on the basis of 8 patient characteristics and the smoking-treatment interaction. OBJECTIVES: This study aimed to assess the ability of the 5-year major adverse cardiovascular event (MACE) model to predict treatment benefit of CABG vs PCI in the SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) and BEST (Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multivessel Coronary Artery Disease) trials. METHODS: This study identified 702 patients with diabetes and MVD to mirror the FREEDOM participants. Discrimination was assessed by C-index, and calibration was assessed by calibration plots in the PCI and CABG arms, respectively. The ability of the FREEDOM score to predict treatment benefit of CABG vs PCI was assessed. RESULTS: Overall, CABG was associated with a lower rate of 5-year MACE compared with PCI (12.4% vs 20.3%; log-rank P = 0.021) irrespective of a history of smoking (Pinteraction = 0.975). Both discrimination and calibration were helpful in the PCI arm (C-index: 0.69; slope: 0.96, intercept: -0.24), but moderate in the CABG arm (C-index: 0.61; slope: 0.61; intercept: -0.53). The FREEDOM score showed some heterogeneity of treatment benefit. CONCLUSIONS: The FREEDOM score could identify some heterogeneity of treatment benefit of CABG vs PCI for 5-year MACE. Until further prospective validations are performed, these results should be taken into consideration when using the FREEDOM score in patients with diabetes and MVD. (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery [SYNTAX]; NCT00114972) (Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multivessel Coronary Artery Disease [BEST]; NCT00997828) (Future Revascularization Evaluation in Patients with Diabetes Mellitus [FREEDOM]; NCT00086450).
引用
- Takahashi K, Serruys PW, Fuster V, et al. External Validation of the FREEDOM Score for Individualized Decision Making Between CABG and PCI. J Am Coll Cardiol. 2022. PMID: 35422242. doi:10.1016/j.jacc.2022.01.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。